The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

June 25, 2027

Study Completion Date

July 2, 2027

Conditions
Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell Transplantation
Interventions
DRUG

Melphalan

"Matched HCT: 100 mg/m\^2 IV on day -2 over 30 minutes. Haplo HCT:~100 mg/m\^2 IV on day -6 over approximately 20-30 minutes."

DRUG

Sirolimus

Sirolimus: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg)\^d, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions and may be modified based on institutional practice.

RADIATION

Total Body Irradiation (TBI)

Haplo HCT only: A dose of 200 cGy will be administered on day -1.

DRUG

Cyclophosphamide

based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.

DRUG

Mycophenolate Mofeti

15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.

DRUG

Fludarabine

Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2

PROCEDURE

Allogeneic HSCT

Stem cell transplant

DRUG

Mesna

equal to the cyclophosphamide dose (50, 35, 25, or 15 mg/kg) as IV infusion concomitant with cyclophosphamide. Mesna is dosed in the same way as cyclophosphamide regarding ideal vs. actual body weight.b Dosing may be modified based on institutional standard practice.

DRUG

Filgrastim

begins on day +5 at a dose of 5 mcg/kg/day (actual body weight; dose rounding is permitted e.g., nearest vial or syringe size) and is administered daily subcutaneously or IV until the absolute neutrophil count is \> 1000 cells/mm3 for three days or \> 5000 for one day.

Trial Locations (2)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

91010

NOT_YET_RECRUITING

City of Hope, Duarte

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH